Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2020 on Wednesday,...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ®...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2020....
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on Wednesday, October 28, 2020,...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its development program for tradipitant. Enrollment in Vanda's Phase...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported that interim analysis showed tradipitant may accelerate clinical improvement in...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2020. "We...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020,...
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in ...
Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA), announced today that Vanda will hold its 2020 Annual Meeting of Stockholders (the "2020 Annual...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos, M.D., President and CEO of Vanda...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2020. "Our...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2020 on Wednesday, May 6, 2020, after ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of the CALYPSO program to study the role that human genetic...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Northwell Health's research arm, The Feinstein Institutes for Medical Research, today announced ...
Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) and the University of Illinois at Chicago (UIC) today announced a research partnership focused on ...
Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will participate at the following upcoming investor conferences in March...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:VNDA) today announced results from a Phase III clinical trial (EPIONE) of tradipitant for the treatment of ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.